191 related articles for article (PubMed ID: 36333289)
1. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer.
Damrauer JS; Beckabir W; Klomp J; Zhou M; Plimack ER; Galsky MD; Grivas P; Hahn NM; O'Donnell PH; Iyer G; Quinn DI; Vincent BG; Quale DZ; Wobker SE; Hoadley KA; Kim WY; Milowsky MI
Nat Commun; 2022 Nov; 13(1):6658. PubMed ID: 36333289
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM
Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
[TBL] [Abstract][Full Text] [Related]
6. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
7. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
Ronan K; Jordan E; Leonard C; McDermott R
Ir J Med Sci; 2024 Jun; 193(3):1155-1161. PubMed ID: 37947995
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
Nakauma-González JA; Rijnders M; van Riet J; van der Heijden MS; Voortman J; Cuppen E; Mehra N; van Wilpe S; Oosting SF; Rijstenberg LL; Westgeest HM; Zwarthoff EC; de Wit R; van der Veldt AAM; van de Werken HJG; Lolkema MPJ; Boormans JL
Eur Urol; 2022 Apr; 81(4):331-336. PubMed ID: 35086719
[TBL] [Abstract][Full Text] [Related]
9. The utility of next generation sequencing in advanced urothelial carcinoma.
Tripathi A; Grivas P
Eur Urol Focus; 2020 Jan; 6(1):41-44. PubMed ID: 31708470
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
Isharwal S; Hu W; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Jadallah S; Loo FL; Pietzak EJ; Cha EK; Bochner BH; Berger MF; Iyer G; Solit DB; Reuter VE; Al-Ahmadie H
J Pathol; 2019 Jul; 248(3):260-265. PubMed ID: 30838648
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
Almassi N; Whiting K; Toubaji A; Lenis AT; Jordan EJ; Won H; Regazzi AM; Chen YB; Gopalan A; Sirintrapun SJ; Fine SW; Tickoo SK; Ostrovnaya I; Pietzak EJ; Cha EK; Goh AC; Donahue TF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Teo MY; Funt SA; Rosenberg JE; Reuter VE; Bajorin DF; Solit DB; Al-Ahmadie H; Iyer G
JCO Precis Oncol; 2022 Jun; 6():e2100392. PubMed ID: 35731998
[TBL] [Abstract][Full Text] [Related]
14. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
15. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
[TBL] [Abstract][Full Text] [Related]
16. Genomic case report of a low grade bladder tumor metastasis to lung.
Van Every MJ; Dancik G; Paramesh V; Gurda GT; Meier DR; Cash SE; Richmond CS; Guin S
BMC Urol; 2018 Sep; 18(1):74. PubMed ID: 30176882
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
18. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
[TBL] [Abstract][Full Text] [Related]
19. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
20. Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
Nakauma-González JA; Rijnders M; Noordsij MTW; Martens JWM; van der Veldt AAM; Lolkema MPJ; Boormans JL; van de Werken HJG
Cell Genom; 2024 Apr; 4(4):100528. PubMed ID: 38552621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
